Monopar Therapeutics Stock EBITDA
| MNPR Stock | USD 34.37 0.14 0.41% |
Monopar Therapeutics fundamentals help investors to digest information that contributes to Monopar Therapeutics' financial success or failures. It also enables traders to predict the movement of Monopar Stock. The fundamental analysis module provides a way to measure Monopar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Monopar Therapeutics stock.
Monopar |
Monopar Therapeutics Company EBITDA Analysis
Monopar Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Monopar Therapeutics EBITDA | 429.04 K |
Most of Monopar Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Monopar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Monopar Therapeutics reported earnings before interest,tax, depreciation and amortization of 429.04 K. This is 99.95% lower than that of the Biotechnology sector and 99.57% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.99% higher than that of the company.
Monopar EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monopar Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics of similar companies.Monopar Therapeutics is currently under evaluation in ebitda category among its peers.
Monopar Fundamentals
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.6 | ||||
| Current Valuation | 201.62 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Shares Owned By Insiders | 37.30 % | ||||
| Shares Owned By Institutions | 42.20 % | ||||
| Number Of Shares Shorted | 32.52 K | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 42.23 X | ||||
| EBITDA | 429.04 K | ||||
| Net Income | (8.4 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 1.76 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 1.40 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Short Ratio | 0.81 X | ||||
| Earnings Per Share | (1.98) X | ||||
| Target Price | 45.67 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 208.89 M | ||||
| Total Asset | 7.35 M | ||||
| Retained Earnings | (60.21 M) | ||||
| Working Capital | 5.58 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
| Net Asset | 7.35 M |
About Monopar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
| 0.61 | VINC | Vincerx Pharma | PairCorr |
| 0.57 | DRRX | Durect Earnings Call This Week | PairCorr |
| 0.54 | DSGN | Design Therapeutics | PairCorr |
| 0.44 | DRMA | Dermata Therapeutics | PairCorr |
| 0.38 | VKTX | Viking Therapeutics | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.